[go: up one dir, main page]

EE03667B1 - Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis - Google Patents

Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis

Info

Publication number
EE03667B1
EE03667B1 EEP199900561A EEP9900561A EE03667B1 EE 03667 B1 EE03667 B1 EE 03667B1 EE P199900561 A EEP199900561 A EE P199900561A EE P9900561 A EEP9900561 A EE P9900561A EE 03667 B1 EE03667 B1 EE 03667B1
Authority
EE
Estonia
Prior art keywords
mammal
alpha
derivative
treatment
composition
Prior art date
Application number
EEP199900561A
Other languages
English (en)
Estonian (et)
Inventor
Haapalinna Antti
Viitamaa Timo
Sallinen Jukka
Scheinin Mika
Savola Juha-Matti
Original Assignee
Haapalinna Antti
Viitamaa Timo
Sallinen Jukka
Scheinin Mika
Savola Juha-Matti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haapalinna Antti, Viitamaa Timo, Sallinen Jukka, Scheinin Mika, Savola Juha-Matti filed Critical Haapalinna Antti
Publication of EE9900561A publication Critical patent/EE9900561A/xx
Publication of EE03667B1 publication Critical patent/EE03667B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP199900561A 1997-05-12 1998-05-11 Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis EE03667B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/854,730 US5902807A (en) 1997-05-12 1997-05-12 Method for the treatment of mental illness in mammals and a composition therefor
PCT/FI1998/000398 WO1998051310A1 (en) 1997-05-12 1998-05-11 A method for the treatment of mental illness in mammals and a composition therefor

Publications (2)

Publication Number Publication Date
EE9900561A EE9900561A (et) 2000-06-15
EE03667B1 true EE03667B1 (et) 2002-04-15

Family

ID=25319419

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900561A EE03667B1 (et) 1997-05-12 1998-05-11 Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis

Country Status (12)

Country Link
US (1) US5902807A (xx)
EP (1) EP1003518A1 (xx)
JP (1) JP2001524979A (xx)
AU (1) AU744096B2 (xx)
BR (1) BR9808784A (xx)
CA (1) CA2288650C (xx)
EE (1) EE03667B1 (xx)
HU (1) HUP0002346A3 (xx)
NO (1) NO995469D0 (xx)
PL (1) PL336771A1 (xx)
SK (1) SK154199A3 (xx)
WO (1) WO1998051310A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
AU2003219199A1 (en) * 2002-04-03 2003-10-13 Orion Corporation Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
DE60316672T2 (de) * 2002-04-03 2008-07-17 Orion Corp. Polycyclische verbindungen als potente alpha2-adrenoceptor antagonisten
KR101195574B1 (ko) * 2002-09-24 2012-10-30 산토리 홀딩스 가부시키가이샤 아라키돈산을 단독으로 또는 도코사헥사엔산과의 조합으로함유하는 인지 능력 향상용 조성물
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP3593797A1 (en) * 2006-12-28 2020-01-15 Suntory Holdings Limited Nerve-regenerating agent
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤

Also Published As

Publication number Publication date
AU7433498A (en) 1998-12-08
HUP0002346A1 (hu) 2001-05-28
NO995469L (no) 1999-11-08
BR9808784A (pt) 2000-08-01
WO1998051310A1 (en) 1998-11-19
CA2288650C (en) 2007-09-25
SK154199A3 (en) 2001-01-18
NO995469D0 (no) 1999-11-08
HUP0002346A3 (en) 2001-09-28
CA2288650A1 (en) 1998-11-19
PL336771A1 (en) 2000-07-17
EP1003518A1 (en) 2000-05-31
JP2001524979A (ja) 2001-12-04
AU744096B2 (en) 2002-02-14
US5902807A (en) 1999-05-11
EE9900561A (et) 2000-06-15

Similar Documents

Publication Publication Date Title
EE05210B1 (et) Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
EE200000232A (et) Farmatseutiline kompositsioon ja selle kasutamine
EE05169B1 (et) Asendatud oksasolidinoonid ja nende kasutamine
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
EE200200484A (et) Väikeseannuseline entekaviiripreparaat ja selle kasutamine
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
NO2011010I1 (no) Naproksen- og esomeprazoltabletter med modifisert frisetting
NO991186L (no) Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes
ID26340A (id) Kapsul ganda dengan penggunaan bahan-bahan aktif dalam berbagai macam pengobatan
EE200200318A (et) Bensasooli derivaadid ja nende kasutamine JNK modulaatoritena
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE03901B1 (et) Elastne vaheriie ja selle kasutamine
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
EE9900524A (et) N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
EE03667B1 (et) Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis
EE05175B1 (et) Asendatud bensimidasooli preparaat, meetod selle valmistamiseks ja selle kasutamine meditsiinis
DE59814201D1 (de) Polybenzoxazol- und Polybenzothiazol-Vorstufen
EE04263B1 (et) Farmatseutiline kompositsioon piperidinoalkanoolantihistamiini ja selle derivaatide biosaadavuse suurendamiseks ning allergiliste reaktsioonide raviks patsiendil
IT1292461B1 (it) Composti fotocromatici,procedimento per la loro preparazione e loro utilizzo in materiali polimerici
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE200100051A (et) Vastavast (-)-stereoisomeerist põhiliselt vaba (+)-nortsisapriidi või selle farmatseutiliselt vastuvõetava soola kasutamine ja farmatseutiline kompositsioon

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20041231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130511